bullish
Astellas (4503) Implications of Ogeda Acquisition
344 Views06 Apr 2017 18:22
At first glance, Astellas Pharma's decision to buy closely-held Belgian biotech firm Ogeda for ¥90bil (US$800mil) is essentially a licensing deal...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Pelham Smithers Associates
Market Intel on Asian Tech with a Japan focus
Price Chart(Sign Up to Access)
- Astellas (4503) Implications of Ogeda Acquisition06 Apr 2017
- Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm24 Aug 2016
- Implications for Astellas as Medivation Invites Offers02 Aug 2016
x